---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087025"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:32:12.104039+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics appoints Helen M. Boudreau, former Novartis CFO, to board

## Summary
- Appointed effective August 2, 2023; term expires at 2024 annual meeting.
- Boudreau brings 30+ years experience; previously COO of Bill & Melinda Gates Medical Research Institute (2018-2019).
- Received initial stock option grant with Black-Scholes value of $350,000, vesting quarterly over three years.
- Will receive annual cash retainer of $50k for director service and $10k for audit committee (pro-rated 2023).
- Appointed to audit committee; currently serves on boards of Premier Inc., Shattuck Labs, and Rallybio.

## SEC filing metadata
- accession: 0001104659-23-087025
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/0001104659-23-087025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/tm2322717d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087025
- JSON: https://secwatch.observer/filing/0001104659-23-087025.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087025.txt

## Key facts
- Executive change
  Helen M. Boudreau was appointed as member of the Board at Tvardi Therapeutics, Inc..
  - Action: appointed
  - Role: member of the Board
  source text: On August 2, 2023, upon the recommendation of its nominating and corporate governance committee, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Helen M. Boudreau, M.B.A. to serve as a member of the Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/0001104659-23-087025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.